Compare YieldMax NVDA Option Income Strategy ETF (NVDY) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
YieldMax NVDA Option Income Strategy ETF vs Repligen Corporation Common Stock — how do they compare? YieldMax NVDA Option Income Strategy ETF trades at $11.99 (market cap $1.39B), while Repligen Corporation Common Stock trades at $178.86 (market cap $11.14B). The key difference: Repligen Corporation Common Stock is far larger — about 8× YieldMax NVDA Option Income Strategy ETF's market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, YieldMax NVDA Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold YieldMax NVDA Option Income Strategy ETF for 44 Days and Repligen Corporation Common Stock for 0 Days on average.
| NVDY | RGEN | |
|---|---|---|
Market Cap | $1.39B | $11.14B |
Volume | 1,855,603 | 1,259,263 |
Sector | Income / Options Overlay | Health |
52-Week High | $17.21 | $194.57 |
52-Week Low | $11.58 | $102.87 |
Typical Hold Time | 44 Days | 0 Days |
Enterprise Value | — | $11.02B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NVDY, the YieldMax NVDA Option Income Strategy ETF, trades at $12.54, up 0.88% on the day. The technical outlook is bearish, with moving averages signaling strong selling pressure, though oscillators are neutral. The fund generates weekly dividends but faces structural limitations on upside participation. Recent news highlights concerns over net asset value erosion despite high distribution yields.
The outlook is cautious; while NVDY offers high income, its strategy caps gains during NVIDIA rallies and may underperform in low-volatility environments. Key risks include NAV decay and reduced option income potential. Investors seeking pure NVIDIA exposure may find direct ownership more attractive for long-term growth.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About YieldMax NVDA Option Income Strategy ETF
NVDY is an actively managed ETF that pursues a synthetic covered call strategy on NVIDIA Corporation (NVDA) stock. The fund primarily sells call options on NVDA and invests in U.S. Treasury securities and other high-quality collateral. Its goal is to generate monthly income from the option premiums. This strategy provides exposure to the high-growth potential of NVDA while seeking to deliver a high yield, though it caps the potential capital appreciation of the stock.
Read more on NVDY →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
